These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 10694102)

  • 21. Multidrug-resistant tuberculosis in children: two cases and a review of the literature.
    Schluger NW; Lawrence RM; McGuiness G; Park M; Rom WN
    Pediatr Pulmonol; 1996 Feb; 21(2):138-42. PubMed ID: 8882216
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
    Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
    J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Childhood tuberculosis: treatment strategies and recent advances.
    Starke JR
    Paediatr Respir Rev; 2001 Jun; 2(2):103-12. PubMed ID: 12531056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug-resistant tuberculosis.
    Iseman MD; Goble M
    N Engl J Med; 1996 Jan; 334(4):267; author reply 268-9. PubMed ID: 8532008
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study].
    Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Yew WW; Chang KC; Chau CH
    J Antimicrob Chemother; 2009 Nov; 64(5):1119; author reply 1119-20. PubMed ID: 19666903
    [No Abstract]   [Full Text] [Related]  

  • 27. A case of DRESS syndrome induced by the antituberculosis drugs, prothionamide, and para-aminosalycilic acid.
    Kim JH; Jang SH; Kim DH; Park S; Kim DG; Jung KS
    Ann Allergy Asthma Immunol; 2013 Feb; 110(2):118-9. PubMed ID: 23352532
    [No Abstract]   [Full Text] [Related]  

  • 28. An effective compromise.
    Reichman LB
    Int J Tuberc Lung Dis; 2005 Oct; 9(10):1061. PubMed ID: 16229215
    [No Abstract]   [Full Text] [Related]  

  • 29. [The role of bacteriology in the treatment of tuberculosis; the Hungarian program].
    Fodor T
    Orv Hetil; 2000 Sep; 141(36):1981-3. PubMed ID: 11031835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.
    Koh WJ; Shim TS
    J Antimicrob Chemother; 2009 Nov; 64(5):1119-20. PubMed ID: 19744986
    [No Abstract]   [Full Text] [Related]  

  • 31. Chemotherapy for tuberculosis. American Thoracic Society.
    Singh V
    Indian Pediatr; 1995 Aug; 32(8):943-4. PubMed ID: 8635851
    [No Abstract]   [Full Text] [Related]  

  • 32. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required?
    Bastian I; Rigouts L; Van Deun A; Portaels F
    Bull World Health Organ; 2000; 78(2):238-51. PubMed ID: 10743297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
    Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
    Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined therapy of pulmonary tuberculosis by using recombinant interleukins].
    Skvortsova LA; Pavlova MV; Vinogradova TI; Archakova LI
    Probl Tuberk Bolezn Legk; 2003; (10):9-12. PubMed ID: 14669620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 36. Once-daily and twice-daily dosing of p-aminosalicylic acid granules.
    Peloquin CA; Berning SE; Huitt GA; Childs JM; Singleton MD; James GT
    Am J Respir Crit Care Med; 1999 Mar; 159(3):932-4. PubMed ID: 10051275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains].
    Han JP; Sun SL; Li RZ; Zhang FS; Wang SC; Cheng J; Deng YF; Wang Y; Yu CB
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Feb; 26(2):70-3. PubMed ID: 12783654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug treatment options for multidrug-resistant tuberculosis.
    Patel K
    Conn Med; 1994 Apr; 58(4):227-30. PubMed ID: 8045123
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
    Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
    Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.